SCHEMBL30748760

SCHEMBL30748760

C[C@@H]1CN(C(=O)OCc2ccccc2)C[C@H](C)N1C(=O)OC(C)(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.57
PDK1 Q15118 1/20 0.53
PDK2 Q15119 1/20 0.53
PDK3 Q15120 1/20 0.53
PDK4 Q16654 1/20 0.53
CACNA1G O43497 1/20 0.50
CACNA1H O95180 1/20 0.50
CACNA1I Q9P0X4 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
HTT P42858 1/20 0.48
CYP2C19 P33261 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
PDE4B Q07343 1/20 0.47
PARP1 P09874 1/20 0.46
GPR119 Q8TDV5 1/20 0.44
AGTR2 P50052 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2044905 1.00 HTR2C (0.57) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL20149925 0.90 PDK1 (0.49) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL3605859 0.89 SMN1; SMN2 (0.50) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL18912624 0.87 SMN1; SMN2 (0.53) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL30789349 0.86 AGTR2 (0.53) HTR2CSMN1; SMN2NPC1RAB9AHTT
SCHEMBL5965723 0.86 AGTR2 (0.53) HTR2CSMN1; SMN2NPC1RAB9AHTT
SCHEMBL30929276 0.86 SMN1; SMN2 (0.49) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL29266950 0.86 SMN1; SMN2 (0.49) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL29266948 0.86 SMN1; SMN2 (0.49) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL6095209 0.86 JAK2 (0.53) HTR2CPDK1PDK2PDK3PDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT HTR2C 2896/4885PDK1 1903/4885PDK2 1678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.